An Investigation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2245035 in Healthy Volunteers and Allergic Rhinitics.

NCT01480271 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

61

Enrollment

INDUSTRY

Sponsor class

Conditions

Rhinitis, Allergic, Seasonal

Interventions

DRUG: 2 ng GSK2445053
DRUG: 20ng GSK2445053
DRUG: 100ng GSK2445053
DRUG: 200ng GSK2445053
DRUG: 400ng GSK2445053
DRUG: 1000ng GSK2445053
DRUG: 2000ng GSK2445053
DRUG: 4000ng GSK2445053
DRUG: Placebo

Sponsor

GlaxoSmithKline